N e w ron platziert neu ausgegebene Aktien im Rahmen der am 18. April 2013 beschlossenen (bis zu 10%) Kapitalerhöhung Montag, 24. Juni 2013 - 07:00

Über Newron Pharmaceuticals

Newron (SIX: NWRN) ist ein biopharmazeutisches Unternehmen, das sich auf neuartige Therapien für Erkrankungen des Zentralen Nervensystems (ZNS) und Schmerzen konzentriert. Das Unternehmen ist in Bresso bei Mailand, Italien, domiziliert. Basierend auf den Phase III-Resultaten von Safinamide zur Therapie der Parkinsons-Krankheit arbeitet Newron zusammen mit seinen Partnern an der raschen Einreichung der weltweiten Registrierungsanträge für das Produkt. Die Zambon Group besitzt die globalen Vermarktungsrechte an Safinamide mit Ausnahme Japans und anderer Schlüsselregionen Asiens und Meiji Seika hat die Rechte, Safinamide in Japan und anderen asiatischen Schlüsselregionen zu entwickeln und zu vermarkten. Zusätzliche Projekte von Newron konzentrieren sich auf vielversprechende seltene Krankheiten und befinden sich in unterschiedlichen Stadien der präklinischen und klinischen Entwicklung, darunter sNN0031 für die Parkinson-Krankheit, Sarizotan für das Rett-Syndrom, sNN0029 für ALS, Ralfinamide für bestimmte Schmerzindikationen und NW-3509 als mögliche erste Add-on-Therapie für die Behandlung von Schizophrenie. www.newron.com

Für weitere Informationen:

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.